当前位置: 首页 >> 检索结果
1. Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.
作者: Klemen Steblovnik.;Ales Blinc.;Mojca Bozic Mijovski.;Misa Fister.;Ursa Mikuz.;Marko Noc.
来源: Circulation. 2016年134卷25期2128-2130页 2. Follow-Up of a Prospective Surgical Strategy to Prevent Intra-Atrial Reentrant Tachycardia After the Fontan Operation.
作者: Ian H Law.;Osman Alam.;Edward L Bove.;Richard G Ohye.;David J Bradley.;Sunkyung Yu.;Macdonald Dick.
来源: Circ Arrhythm Electrophysiol. 2016年9卷12期
Intra-atrial reentrant tachycardia (IART) after the Fontan operation had an early reported incidence of 10% to 35% during early and intermediate follow-up and posed substantial management challenges.
3. INNOVATION Study (Impact of Immediate Stent Implantation Versus Deferred Stent Implantation on Infarct Size and Microvascular Perfusion in Patients With ST-Segment-Elevation Myocardial Infarction).
作者: Je Sang Kim.;Hyun Jong Lee.;Cheol Woong Yu.;Yang Min Kim.;Soon Jun Hong.;Jae Hyung Park.;Rak Kyeong Choi.;Young Jin Choi.;Jin Sik Park.;Tae Hoon Kim.;Ho-Jun Jang.;Hyung Joon Joo.;Sang-A Cho.;Young Moo Ro.;Do-Sun Lim.
来源: Circ Cardiovasc Interv. 2016年9卷12期
The aim of this study was to assess whether deferred stenting (DS) reduces infarct size and microvascular obstruction (MVO) compared with immediate stenting (IS) in primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction.
4. Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke: Analysis of 2 Randomized Controlled Trials.
作者: Andrew Bivard.;Xuya Huang.;Patrick McElduff.;Christopher R Levi.;Bruce C V Campbell.;Bharath Kumar Cheripelli.;Dheeraj Kalladka.;Fiona Catherine Moreton.;Ian Ford.;Christopher F Bladin.;Stephen M Davis.;Geoffrey A Donnan.;Keith W Muir.;Mark W Parsons.
来源: Circulation. 2017年135卷5期440-448页
We pooled 2 clinical trials of tenecteplase compared with alteplase for the treatment of acute ischemic stroke, 1 that demonstrated superiority of tenecteplase and the other that showed no difference between the treatments in patient clinical outcomes. We tested the hypotheses that reperfusion therapy with tenecteplase would be superior to alteplase in improving functional outcomes in the group of patients with target mismatch as identified with advanced imaging.
5. Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin: A Multicenter 18F-Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Study.
作者: Parmanand Singh.;Hamed Emami.;Sharath Subramanian.;Pal Maurovich-Horvat.;Gergana Marincheva-Savcheva.;Hector M Medina.;Amr Abdelbaky.;Achilles Alon.;Sudha S Shankar.;James H F Rudd.;Zahi A Fayad.;Udo Hoffmann.;Ahmed Tawakol.
来源: Circ Cardiovasc Imaging. 2016年9卷12期e004195页
Nonobstructive coronary plaques manifesting high-risk morphology (HRM) associate with an increased risk of adverse clinical cardiovascular events. We sought to test the hypothesis that statins have a greater anti-inflammatory effect within coronary plaques containing HRM.
6. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
作者: Gerald F Watts.;Dick C Chan.;Ricardo Dent.;Ransi Somaratne.;Scott M Wasserman.;Rob Scott.;Sally Burrows.;P Hugh R Barrett.
来源: Circulation. 2017年135卷4期338-351页
Monoclonal antibodies against proprotein convertase subtilisin kexin type 9 (PCSK9), such as evolocumab, lower plasma low-density lipoprotein (LDL)-cholesterol concentrations. Evolocumab is under investigation for its effects on cardiovascular outcomes in statin-treated, high-risk patients. The mechanism of action of PCSK9 monoclonal antibodies on lipoprotein metabolism remains to be fully evaluated. Stable isotope tracer kinetics can effectively elucidate the mode of action of new lipid-regulating pharmacotherapies.
7. Effects of Liraglutide on Reperfusion Injury in Patients With ST-Segment-Elevation Myocardial Infarction.
作者: Wei Ren Chen.;Yun Dai Chen.;Feng Tian.;Na Yang.;Liu Quan Cheng.;Shun Ying Hu.;Jing Wang.;Jun Jie Yang.;Shi Feng Wang.;Xiao Fang Gu.
来源: Circ Cardiovasc Imaging. 2016年9卷12期
Liraglutide, a glucagon-like peptide-1 analog, was reported to reduce reperfusion injury in mice. We planned to evaluate the effects of liraglutide on reperfusion injury in patients with acute ST-segment-elevation myocardial infarction treated with primary percutaneous coronary intervention.
8. Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy).
作者: Neal A Chatterjee.;Michael R Gold.;Alan D Waggoner.;Michael H Picard.;Kenneth M Stein.;Yinghong Yu.;Timothy E Meyer.;Nicholas Wold.;Kenneth A Ellenbogen.;Jagmeet P Singh.
来源: Circ Arrhythm Electrophysiol. 2016年9卷11期
Mitral regurgitation (MR) is associated with worse survival in those undergoing cardiac resynchronization therapy (CRT). Left ventricular (LV) lead position in CRT may ameliorate mechanisms of MR. We examine the association between a longer LV electric delay (QLV) at the LV stimulation site and MR reduction after CRT.
9. The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the Accuracy of Physiological Indices of Functional Stenosis Severity).
作者: Gilbert W M Wijntjens.;Tim P van de Hoef.;Robin P Kraak.;Marcel A Beijk.;Krischan D Sjauw.;M Marije Vis.;Maribel I Madera Cambero.;Stijn L Brinckman.;Jacobus Plomp.;Jan Baan.;Karel T Koch.;Joanna J Wykrzykowska.;José P Henriques.;Robbert J de Winter.;Jan J Piek.
来源: Circ Cardiovasc Interv. 2016年9卷12期
The Navvus pressure sensor-equipped microcatheter allows to measure functional stenosis severity over a work-horse guidewire and is used as a more feasible alternative to regular sensor-equipped wires. However, Navvus is larger in diameter than contemporary sensor-equipped guidewires and may, thereby, influence functional measurements. The present study evaluates the hemodynamic influence of the Navvus microcatheter.
10. Impact of Body Mass Index on the Accuracy of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide for Predicting Outcomes in Patients With Chronic Heart Failure and Reduced Ejection Fraction: Insights From the PARADIGM-HF Study (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial).
作者: Wilson Nadruz.;Brian L Claggett.;John J McMurray.;Milton Packer.;Michael R Zile.;Jean L Rouleau.;Akshay S Desai.;Karl Swedberg.;Martin Lefkowitz.;Victor C Shi.;Margaret F Prescott.;Scott D Solomon.
来源: Circulation. 2016年134卷22期1785-1787页 11. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial.
作者: Yoshihiko Saito.;Sadanori Okada.;Hisao Ogawa.;Hirofumi Soejima.;Mio Sakuma.;Masafumi Nakayama.;Naofumi Doi.;Hideaki Jinnouchi.;Masako Waki.;Izuru Masuda.;Takeshi Morimoto.; .
来源: Circulation. 2017年135卷7期659-670页
The long-term efficacy and safety of low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus are still inconclusive.
12. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
作者: C Michael Gibson.;Serge Korjian.;Pierluigi Tricoci.;Yazan Daaboul.;Megan Yee.;Purva Jain.;John H Alexander.;P Gabriel Steg.;A Michael Lincoff.;John J P Kastelein.;Roxana Mehran.;Denise M D'Andrea.;Lawrence I Deckelbaum.;Bela Merkely.;Maciej Zarebinski.;Ton Oude Ophuis.;Robert A Harrington.
来源: Circulation. 2016年134卷24期1918-1930页
Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal subjects or those with stable coronary artery disease. This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acute myocardial infarction.
13. Nitrite and S-Nitrosohemoglobin Exchange Across the Human Cerebral and Femoral Circulation: Relationship to Basal and Exercise Blood Flow Responses to Hypoxia.
作者: Damian M Bailey.;Peter Rasmussen.;Morten Overgaard.;Kevin A Evans.;Aske M Bohm.;Thomas Seifert.;Patrice Brassard.;Morten Zaar.;Henning B Nielsen.;Peter B Raven.;Niels H Secher.
来源: Circulation. 2017年135卷2期166-176页
The mechanisms underlying red blood cell (RBC)-mediated hypoxic vasodilation remain controversial, with separate roles for nitrite () and S-nitrosohemoglobin (SNO-Hb) widely contested given their ability to transduce nitric oxide bioactivity within the microcirculation. To establish their relative contribution in vivo, we quantified arterial-venous concentration gradients across the human cerebral and femoral circulation at rest and during exercise, an ideal model system characterized by physiological extremes of O2 tension and blood flow.
14. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
作者: C Michael Gibson.;Duane S Pinto.;Gerald Chi.;Douglas Arbetter.;Megan Yee.;Roxana Mehran.;Christoph Bode.;Jonathan Halperin.;Freek W A Verheugt.;Peter Wildgoose.;Paul Burton.;Martin van Eickels.;Serge Korjian.;Yazan Daaboul.;Purva Jain.;Gregory Y H Lip.;Marc Cohen.;Eric D Peterson.;Keith A A Fox.
来源: Circulation. 2017年135卷4期323-333页
Patients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT), yet this treatment leads to high risks of bleeding. We hypothesized that a regimen of rivaroxaban plus a P2Y12 inhibitor monotherapy or rivaroxaban plus DAPT could reduce bleeding and thereby have a favorable impact on all-cause mortality and the need for rehospitalization.
15. Methylenetetrahydrofolate Dehydrogenase 1 Polymorphisms Modify the Associations of Plasma Glycine and Serine With Risk of Acute Myocardial Infarction in Patients With Stable Angina Pectoris in WENBIT (Western Norway B Vitamin Intervention Trial).
作者: Yunpeng Ding.;Eva R Pedersen.;Gard F T Svingen.;Øyvind Helgeland.;Jesse F Gregory.;Kjetil H Løland.;Klaus Meyer.;Grethe S Tell.;Per M Ueland.;Ottar K Nygård.
来源: Circ Cardiovasc Genet. 2016年9卷6期541-547页
Serine and glycine interconversion and methylenetetrahydrofolate dehydrogenase 1 (MTHFD1)-mediated 1-carbon transfer are the major sources of methyl groups for 1-carbon metabolism. Recently, plasma glycine and a common polymorphism in MTHFD1 have been associated with risk of acute myocardial infarction (AMI). It is, therefore, of interest to explore if these 2 pathways interact in relation to AMI.
16. Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease.
作者: W Schuyler Jones.;Iris Baumgartner.;William R Hiatt.;Gretchen Heizer.;Michael S Conte.;Christopher J White.;Jeffrey S Berger.;Peter Held.;Brian G Katona.;Kenneth W Mahaffey.;Lars Norgren.;Juuso Blomster.;Marcus Millegård.;Craig Reist.;Manesh R Patel.;F Gerry R Fowkes.; .
来源: Circulation. 2017年135卷3期241-250页
In patients with symptomatic peripheral artery disease with a history of limb revascularization, the optimal antithrombotic regimen for long-term management is unknown.
17. Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial.
作者: Sebastian Wiberg.;Christian Hassager.;Henrik Schmidt.;Jakob Hartvig Thomsen.;Martin Frydland.;Matias Greve Lindholm.;Dan Eik Høfsten.;Thomas Engstrøm.;Lars Køber.;Jacob Eifer Møller.;Jesper Kjaergaard.
来源: Circulation. 2016年134卷25期2115-2124页
In-hospital mortality in comatose patients resuscitated from out-of-hospital cardiac arrest (OHCA) is ≈50%. In OHCA patients, the leading cause of death is neurological injury secondary to ischemia and reperfusion. Glucagon-like peptide-1 analogs are approved for type 2 diabetes mellitus; preclinical and clinical data have suggested their organ-protective effects in patients with ischemia and reperfusion injury. The aim of this trial was to investigate the neuroprotective effects of the glucagon-like peptide-1 analog exenatide in resuscitated OHCA patients.
18. Sealing Intermediate Nonobstructive Coronary Saphenous Vein Graft Lesions With Drug-Eluting Stents as a New Approach to Reducing Cardiac Events: A Randomized Controlled Trial.
作者: Josep Rodés-Cabau.;Sanjit S Jolly.;John Cairns.;Samer Mansour.;Philippe L L'Allier.;Patrick J Teefy.;John J Graham.;Michel R Le May.;Warren J Cantor.;David Wood.;Kumar Balasubramanian.;Robert DeLarochellière.;Vlad Dzavik.; .
来源: Circ Cardiovasc Interv. 2016年9卷11期
The objective of this study was to assess the efficacy of sealing intermediate nonobstructive coronary saphenous vein graft (SVG) lesions with drug-eluting stents (DES; paclitaxel- or everolimus-eluting stents) for reducing major adverse cardiac events (MACE).
19. PCI Choice Decision Aid for Stable Coronary Artery Disease: A Randomized Trial.
作者: Megan Coylewright.;Sara Dick.;Becky Zmolek.;Jason Askelin.;Edward Hawkins.;Megan Branda.;Jonathan W Inselman.;Claudia Zeballos-Palacios.;Nilay D Shah.;Erik P Hess.;Annie LeBlanc.;Victor M Montori.;Henry H Ting.
来源: Circ Cardiovasc Qual Outcomes. 2016年9卷6期767-776页
Percutaneous coronary intervention (PCI) for stable coronary artery disease does not reduce the risk of death and myocardial infarction compared with optimal medical therapy (OMT), but many patients think otherwise. PCI Choice, a decision aid (DA), was designed for use during the clinical visit and includes information on quality of life and mortality outcomes for PCI with OMT versus OMT alone for stable coronary artery disease.
20. Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target? An Antagonist View From the HOPE-3 Trial (Heart Outcomes Evaluation-3). |